First-generation texosome-based delivery system for cancer therapy
| Source of texosome | Treatment protocol | Type of cancer | Outcome | Ref |
|---|---|---|---|---|
| L1210 cell line | Vaccination with texosomes | Leukemia | Inhibitory impact on tumor growth, CTL mediated antitumor immunity | 84 |
| A20 (H-2d) B cell lymphoma/leukemia cell line, CT-26 colon adenocarcinoma cells | Vaccination with heat shocked texosome and texosome | Lymphoma, colon cancer, leukemia | CTL mediated antitumor immunity, heat stress produces texosome with higher efficiency against tumor | 85 |
| CT26 mouse colon carcinoma cells, B16-F1 mouse melanoma cells | Vaccination with dendritic cells pulsed with heat shock texosomes | Melanoma, colon cancer | Th1-mediated antitumor responses, rise IgG2a and IFN-γ production | 86 |
| CT26 and TA3HA mouse cell line | Vaccination with texosome derived from cell transfected with human MUC1 | Colon cancer | Immune cell activation, inhibitory effect on growth of hMUC1-expressing tumor | 87 |
| Several pancreatic cancer cell lines | In vitro treatment with texosome | Pancreatic cancer | Stimulation of mitochondria mediated apoptosis and through p13k/Akt/GSK-3β | 88 |
| Soj-6 pancreatic cancer cell line | In vitro treatment with texosomes | Pancreatic cancer | Triggering apoptosis based on notch signaling | 89 |
| Dendritic cells pulsed with texosome | Mesothelioma | Robust CTL mediated antitumor immunity | 82 |